Concepts (287)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Smoking Cessation | 20 | 2025 | 269 | 7.720 |
Why?
|
| Electronic Nicotine Delivery Systems | 26 | 2025 | 72 | 7.310 |
Why?
|
| Tobacco Products | 22 | 2024 | 77 | 5.990 |
Why?
|
| Vaping | 14 | 2025 | 43 | 4.400 |
Why?
|
| Cigarette Smoking | 10 | 2025 | 47 | 3.860 |
Why?
|
| Social Media | 12 | 2024 | 111 | 3.330 |
Why?
|
| N-Methyl-3,4-methylenedioxyamphetamine | 11 | 2020 | 74 | 2.800 |
Why?
|
| Affect | 11 | 2025 | 396 | 2.490 |
Why?
|
| Substance Withdrawal Syndrome | 8 | 2024 | 53 | 2.460 |
Why?
|
| Oxytocin | 6 | 2024 | 75 | 2.170 |
Why?
|
| Marketing | 7 | 2022 | 23 | 2.150 |
Why?
|
| Methamphetamine | 9 | 2021 | 104 | 2.120 |
Why?
|
| Tobacco Use Disorder | 8 | 2024 | 121 | 1.990 |
Why?
|
| Central Nervous System Stimulants | 12 | 2018 | 233 | 1.860 |
Why?
|
| Mindfulness | 2 | 2024 | 19 | 1.650 |
Why?
|
| Emotions | 7 | 2017 | 372 | 1.550 |
Why?
|
| Hallucinogens | 6 | 2016 | 83 | 1.440 |
Why?
|
| Social Behavior | 9 | 2023 | 307 | 1.430 |
Why?
|
| Administration, Intranasal | 10 | 2024 | 140 | 1.310 |
Why?
|
| Ethanol | 4 | 2021 | 273 | 1.290 |
Why?
|
| Tobacco Industry | 3 | 2024 | 7 | 1.290 |
Why?
|
| Young Adult | 39 | 2025 | 6930 | 1.280 |
Why?
|
| Flavoring Agents | 6 | 2021 | 11 | 1.260 |
Why?
|
| Nicotine | 11 | 2025 | 208 | 1.220 |
Why?
|
| Video Games | 2 | 2021 | 12 | 1.210 |
Why?
|
| Motivation | 8 | 2022 | 310 | 1.170 |
Why?
|
| Dextroamphetamine | 6 | 2018 | 108 | 1.150 |
Why?
|
| Depression | 6 | 2025 | 544 | 1.150 |
Why?
|
| Smokers | 4 | 2021 | 54 | 1.050 |
Why?
|
| Double-Blind Method | 22 | 2020 | 1729 | 1.040 |
Why?
|
| Adult | 50 | 2025 | 27918 | 1.040 |
Why?
|
| Substance-Related Disorders | 9 | 2023 | 441 | 1.000 |
Why?
|
| Humans | 95 | 2025 | 93515 | 0.990 |
Why?
|
| Smoking | 11 | 2023 | 648 | 0.980 |
Why?
|
| Psychomotor Performance | 7 | 2011 | 497 | 0.970 |
Why?
|
| Adolescent | 34 | 2025 | 9606 | 0.910 |
Why?
|
| Male | 59 | 2025 | 44557 | 0.900 |
Why?
|
| Underage Drinking | 3 | 2021 | 3 | 0.850 |
Why?
|
| Adolescent Behavior | 7 | 2020 | 111 | 0.840 |
Why?
|
| Female | 59 | 2025 | 48702 | 0.830 |
Why?
|
| Social Facilitation | 2 | 2021 | 8 | 0.820 |
Why?
|
| Students | 5 | 2021 | 179 | 0.810 |
Why?
|
| Tobacco Use Cessation | 1 | 2023 | 9 | 0.790 |
Why?
|
| Dehydroepiandrosterone | 1 | 2023 | 45 | 0.790 |
Why?
|
| Cognitive Dysfunction | 1 | 2025 | 190 | 0.750 |
Why?
|
| Mobile Applications | 1 | 2023 | 78 | 0.740 |
Why?
|
| Tobacco Use | 7 | 2022 | 29 | 0.720 |
Why?
|
| Heart Rate | 6 | 2016 | 505 | 0.690 |
Why?
|
| Blood Pressure | 7 | 2016 | 896 | 0.690 |
Why?
|
| Binge Drinking | 1 | 2021 | 15 | 0.660 |
Why?
|
| Self Efficacy | 1 | 2021 | 58 | 0.660 |
Why?
|
| Risk-Taking | 2 | 2021 | 158 | 0.650 |
Why?
|
| Amphetamine-Related Disorders | 3 | 2012 | 29 | 0.640 |
Why?
|
| Healthy Volunteers | 5 | 2018 | 148 | 0.640 |
Why?
|
| Sleep | 4 | 2011 | 448 | 0.630 |
Why?
|
| Sleep Disorders, Circadian Rhythm | 2 | 2010 | 11 | 0.610 |
Why?
|
| Consumer Behavior | 1 | 2019 | 31 | 0.600 |
Why?
|
| Cognition | 6 | 2015 | 627 | 0.600 |
Why?
|
| Behavior, Addictive | 3 | 2023 | 137 | 0.580 |
Why?
|
| Analgesics, Opioid | 5 | 2025 | 513 | 0.580 |
Why?
|
| Personality | 3 | 2015 | 140 | 0.550 |
Why?
|
| Amphetamine | 2 | 2016 | 101 | 0.550 |
Why?
|
| Health Education | 1 | 2018 | 105 | 0.550 |
Why?
|
| Attitude to Health | 2 | 2018 | 217 | 0.540 |
Why?
|
| Dose-Response Relationship, Drug | 10 | 2016 | 1914 | 0.540 |
Why?
|
| Social Networking | 1 | 2018 | 85 | 0.540 |
Why?
|
| Surveys and Questionnaires | 13 | 2021 | 2802 | 0.510 |
Why?
|
| Impulsive Behavior | 3 | 2019 | 290 | 0.510 |
Why?
|
| Music | 3 | 2022 | 35 | 0.500 |
Why?
|
| Social Environment | 2 | 2016 | 194 | 0.500 |
Why?
|
| Marijuana Use | 3 | 2020 | 11 | 0.470 |
Why?
|
| Individuality | 2 | 2018 | 114 | 0.470 |
Why?
|
| California | 3 | 2025 | 158 | 0.460 |
Why?
|
| Choice Behavior | 3 | 2014 | 159 | 0.430 |
Why?
|
| Serotonin Agents | 1 | 2014 | 13 | 0.420 |
Why?
|
| Empathy | 2 | 2015 | 150 | 0.410 |
Why?
|
| Intention | 3 | 2022 | 52 | 0.390 |
Why?
|
| Alcoholic Intoxication | 1 | 2013 | 37 | 0.380 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2013 | 43 | 0.370 |
Why?
|
| Cross-Sectional Studies | 7 | 2025 | 1847 | 0.370 |
Why?
|
| Parents | 2 | 2025 | 292 | 0.350 |
Why?
|
| Self Report | 7 | 2022 | 328 | 0.340 |
Why?
|
| Sex Factors | 2 | 2024 | 1105 | 0.340 |
Why?
|
| Neoplasms | 2 | 2023 | 3169 | 0.330 |
Why?
|
| Eating | 1 | 2011 | 162 | 0.320 |
Why?
|
| Alcohol Drinking | 1 | 2013 | 283 | 0.320 |
Why?
|
| Hypnotics and Sedatives | 2 | 2013 | 137 | 0.320 |
Why?
|
| Health Behavior | 2 | 2022 | 182 | 0.310 |
Why?
|
| Reward | 5 | 2019 | 209 | 0.280 |
Why?
|
| Pyridines | 1 | 2010 | 303 | 0.280 |
Why?
|
| Los Angeles | 5 | 2020 | 28 | 0.270 |
Why?
|
| Internal-External Control | 1 | 2007 | 45 | 0.270 |
Why?
|
| Speech | 2 | 2020 | 90 | 0.260 |
Why?
|
| Psychotropic Drugs | 2 | 2020 | 82 | 0.250 |
Why?
|
| Anxiety Disorders | 3 | 2019 | 155 | 0.240 |
Why?
|
| Self Administration | 3 | 2012 | 76 | 0.240 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2021 | 624 | 0.230 |
Why?
|
| Arousal | 3 | 2018 | 171 | 0.230 |
Why?
|
| Exercise | 2 | 2020 | 353 | 0.230 |
Why?
|
| Pamphlets | 1 | 2025 | 14 | 0.220 |
Why?
|
| Anxiety | 2 | 2019 | 337 | 0.220 |
Why?
|
| Awareness | 1 | 2025 | 89 | 0.220 |
Why?
|
| Administration, Oral | 4 | 2018 | 657 | 0.210 |
Why?
|
| Nicotine Chewing Gum | 1 | 2024 | 3 | 0.210 |
Why?
|
| Hostility | 1 | 2024 | 25 | 0.210 |
Why?
|
| Middle Aged | 8 | 2025 | 27573 | 0.200 |
Why?
|
| United States | 8 | 2025 | 7622 | 0.200 |
Why?
|
| Dehydroepiandrosterone Sulfate | 1 | 2023 | 14 | 0.200 |
Why?
|
| Attentional Bias | 1 | 2023 | 10 | 0.200 |
Why?
|
| Product Labeling | 2 | 2013 | 3 | 0.200 |
Why?
|
| Alkaloids | 2 | 2013 | 47 | 0.200 |
Why?
|
| Buprenorphine | 1 | 2024 | 52 | 0.200 |
Why?
|
| Pain Management | 1 | 2025 | 180 | 0.190 |
Why?
|
| Drug Overdose | 1 | 2024 | 89 | 0.190 |
Why?
|
| Schools | 2 | 2020 | 84 | 0.180 |
Why?
|
| Minority Groups | 1 | 2023 | 149 | 0.180 |
Why?
|
| Patient Education as Topic | 1 | 2025 | 373 | 0.180 |
Why?
|
| Marijuana Smoking | 2 | 2019 | 28 | 0.180 |
Why?
|
| Pain, Postoperative | 2 | 2021 | 276 | 0.170 |
Why?
|
| Racism | 1 | 2023 | 104 | 0.170 |
Why?
|
| Smoke | 1 | 2021 | 29 | 0.170 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2025 | 557 | 0.160 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2021 | 66 | 0.160 |
Why?
|
| Internet | 2 | 2020 | 337 | 0.160 |
Why?
|
| Opioid-Related Disorders | 1 | 2024 | 233 | 0.160 |
Why?
|
| Pain | 2 | 2024 | 414 | 0.160 |
Why?
|
| Premenopause | 1 | 2020 | 63 | 0.160 |
Why?
|
| Plants, Edible | 1 | 2019 | 2 | 0.160 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 97 | 0.150 |
Why?
|
| Product Packaging | 1 | 2019 | 1 | 0.150 |
Why?
|
| Mood Disorders | 1 | 2020 | 82 | 0.150 |
Why?
|
| Government Regulation | 1 | 2019 | 49 | 0.150 |
Why?
|
| Work Schedule Tolerance | 2 | 2010 | 34 | 0.150 |
Why?
|
| Aromatherapy | 1 | 2019 | 1 | 0.150 |
Why?
|
| Antidepressive Agents | 1 | 2020 | 109 | 0.150 |
Why?
|
| Taste | 1 | 2019 | 29 | 0.150 |
Why?
|
| Cannabis | 1 | 2019 | 38 | 0.150 |
Why?
|
| Behavior Therapy | 1 | 2020 | 93 | 0.150 |
Why?
|
| Nebulizers and Vaporizers | 1 | 2019 | 62 | 0.150 |
Why?
|
| Pleasure | 2 | 2015 | 14 | 0.140 |
Why?
|
| Cartoons as Topic | 1 | 2018 | 3 | 0.140 |
Why?
|
| Pilot Projects | 2 | 2019 | 917 | 0.140 |
Why?
|
| Language | 1 | 2020 | 158 | 0.140 |
Why?
|
| Commerce | 1 | 2018 | 29 | 0.140 |
Why?
|
| Economics, Behavioral | 1 | 2018 | 7 | 0.140 |
Why?
|
| Risk Factors | 6 | 2020 | 5899 | 0.130 |
Why?
|
| Attitude | 1 | 2018 | 132 | 0.130 |
Why?
|
| Neuropsychological Tests | 1 | 2020 | 543 | 0.130 |
Why?
|
| Drug Interactions | 2 | 2015 | 239 | 0.130 |
Why?
|
| Cluster Analysis | 1 | 2018 | 391 | 0.130 |
Why?
|
| Anhedonia | 1 | 2017 | 13 | 0.130 |
Why?
|
| Progesterone | 1 | 2017 | 112 | 0.130 |
Why?
|
| Health Promotion | 1 | 2018 | 170 | 0.130 |
Why?
|
| Patient Selection | 1 | 2021 | 690 | 0.130 |
Why?
|
| Designer Drugs | 2 | 2013 | 4 | 0.120 |
Why?
|
| Estradiol | 1 | 2017 | 247 | 0.120 |
Why?
|
| Comorbidity | 2 | 2017 | 1007 | 0.120 |
Why?
|
| Pharmacogenomic Variants | 1 | 2016 | 45 | 0.120 |
Why?
|
| Principal Component Analysis | 2 | 2016 | 167 | 0.120 |
Why?
|
| Premenstrual Syndrome | 1 | 2016 | 2 | 0.120 |
Why?
|
| Self-Control | 1 | 2016 | 11 | 0.120 |
Why?
|
| Receptors, Oxytocin | 1 | 2016 | 10 | 0.120 |
Why?
|
| Neuropeptides | 1 | 2016 | 114 | 0.120 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2016 | 33 | 0.120 |
Why?
|
| Neurotransmitter Agents | 1 | 2016 | 102 | 0.120 |
Why?
|
| Panic Disorder | 1 | 2015 | 21 | 0.120 |
Why?
|
| Craving | 1 | 2016 | 24 | 0.120 |
Why?
|
| Visual Analog Scale | 1 | 2015 | 18 | 0.110 |
Why?
|
| Cell Adhesion Molecules, Neuronal | 1 | 2015 | 29 | 0.110 |
Why?
|
| Cross-Over Studies | 2 | 2016 | 390 | 0.110 |
Why?
|
| Cadherins | 1 | 2016 | 180 | 0.110 |
Why?
|
| Autism Spectrum Disorder | 1 | 2016 | 87 | 0.110 |
Why?
|
| Prospective Studies | 2 | 2021 | 4560 | 0.110 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2015 | 502 | 0.110 |
Why?
|
| Social Class | 1 | 2015 | 141 | 0.110 |
Why?
|
| Time Factors | 2 | 2014 | 5410 | 0.100 |
Why?
|
| Focus Groups | 2 | 2025 | 184 | 0.100 |
Why?
|
| Genome-Wide Association Study | 3 | 2016 | 1762 | 0.100 |
Why?
|
| Psychoses, Substance-Induced | 1 | 2013 | 7 | 0.100 |
Why?
|
| Drug and Narcotic Control | 1 | 2013 | 6 | 0.100 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2016 | 2484 | 0.100 |
Why?
|
| Diphenhydramine | 1 | 2013 | 14 | 0.100 |
Why?
|
| Breath Tests | 1 | 2013 | 58 | 0.100 |
Why?
|
| Depressive Disorder, Major | 1 | 2015 | 171 | 0.100 |
Why?
|
| Alcoholism | 1 | 2015 | 188 | 0.100 |
Why?
|
| Emergency Treatment | 1 | 2013 | 47 | 0.100 |
Why?
|
| Photic Stimulation | 2 | 2014 | 509 | 0.090 |
Why?
|
| Pharmacogenetics | 1 | 2016 | 456 | 0.090 |
Why?
|
| Euphoria | 1 | 2013 | 47 | 0.090 |
Why?
|
| Linear Models | 1 | 2014 | 413 | 0.090 |
Why?
|
| Fear | 1 | 2013 | 88 | 0.090 |
Why?
|
| Psychomotor Disorders | 1 | 2012 | 20 | 0.090 |
Why?
|
| New York | 1 | 2012 | 76 | 0.090 |
Why?
|
| Stress, Psychological | 1 | 2015 | 342 | 0.090 |
Why?
|
| HIV Infections | 1 | 2021 | 961 | 0.090 |
Why?
|
| United States Food and Drug Administration | 2 | 2024 | 142 | 0.090 |
Why?
|
| Research Design | 1 | 2015 | 617 | 0.090 |
Why?
|
| Reproducibility of Results | 2 | 2015 | 2715 | 0.090 |
Why?
|
| Retrospective Studies | 2 | 2023 | 10164 | 0.080 |
Why?
|
| Predictive Value of Tests | 1 | 2015 | 1713 | 0.080 |
Why?
|
| Ambulatory Care | 1 | 2012 | 193 | 0.080 |
Why?
|
| Work | 1 | 2010 | 15 | 0.080 |
Why?
|
| Hemodynamics | 1 | 2014 | 713 | 0.080 |
Why?
|
| Cohort Studies | 3 | 2023 | 3054 | 0.070 |
Why?
|
| Administration, Cutaneous | 2 | 2020 | 61 | 0.070 |
Why?
|
| Wakefulness | 1 | 2008 | 131 | 0.070 |
Why?
|
| Adrenergic Agents | 1 | 2007 | 6 | 0.070 |
Why?
|
| Fatigue | 1 | 2008 | 181 | 0.070 |
Why?
|
| Orientation | 1 | 2007 | 111 | 0.060 |
Why?
|
| Behavior | 1 | 2007 | 85 | 0.060 |
Why?
|
| Homosexuality | 1 | 1987 | 10 | 0.060 |
Why?
|
| Judgment | 1 | 2007 | 69 | 0.060 |
Why?
|
| Mother-Child Relations | 1 | 1987 | 31 | 0.060 |
Why?
|
| Maternal Behavior | 1 | 1987 | 55 | 0.060 |
Why?
|
| Pattern Recognition, Visual | 1 | 2007 | 158 | 0.060 |
Why?
|
| Selection, Genetic | 1 | 1990 | 538 | 0.060 |
Why?
|
| Cardiovascular Diseases | 1 | 2012 | 754 | 0.060 |
Why?
|
| Models, Genetic | 1 | 1990 | 970 | 0.050 |
Why?
|
| Chewing Gum | 1 | 2024 | 4 | 0.050 |
Why?
|
| Psychometrics | 2 | 2015 | 337 | 0.050 |
Why?
|
| Heroin | 1 | 2024 | 14 | 0.050 |
Why?
|
| Baths | 2 | 2013 | 10 | 0.050 |
Why?
|
| Salts | 2 | 2013 | 18 | 0.050 |
Why?
|
| Multifactorial Inheritance | 2 | 2015 | 202 | 0.050 |
Why?
|
| Fentanyl | 1 | 2024 | 86 | 0.050 |
Why?
|
| Menthol | 1 | 2022 | 5 | 0.050 |
Why?
|
| Ice | 1 | 2022 | 11 | 0.050 |
Why?
|
| Biological Evolution | 1 | 1990 | 1020 | 0.050 |
Why?
|
| Laboratories | 1 | 2022 | 46 | 0.040 |
Why?
|
| Needle Sharing | 1 | 2021 | 15 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 3830 | 0.040 |
Why?
|
| Psycholinguistics | 1 | 2020 | 10 | 0.040 |
Why?
|
| Drug Prescriptions | 1 | 2021 | 150 | 0.040 |
Why?
|
| Adolescent Health | 1 | 2019 | 5 | 0.040 |
Why?
|
| Semantics | 1 | 2020 | 55 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2019 | 174 | 0.040 |
Why?
|
| Temperament | 1 | 2019 | 28 | 0.040 |
Why?
|
| Tobacco, Smokeless | 1 | 2018 | 10 | 0.040 |
Why?
|
| Depressive Disorder | 1 | 2019 | 225 | 0.030 |
Why?
|
| Models, Psychological | 1 | 2018 | 164 | 0.030 |
Why?
|
| Multilevel Analysis | 1 | 2016 | 25 | 0.030 |
Why?
|
| Saliva | 1 | 2017 | 124 | 0.030 |
Why?
|
| Diet | 1 | 2020 | 460 | 0.030 |
Why?
|
| Age Factors | 1 | 2021 | 1906 | 0.030 |
Why?
|
| Ovary | 1 | 2017 | 254 | 0.030 |
Why?
|
| Models, Statistical | 1 | 2019 | 585 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2021 | 660 | 0.030 |
Why?
|
| Ganglionic Stimulants | 1 | 2015 | 7 | 0.030 |
Why?
|
| Placebos | 1 | 2016 | 206 | 0.030 |
Why?
|
| Cell Phone | 1 | 2016 | 39 | 0.030 |
Why?
|
| Neuroticism | 1 | 2015 | 5 | 0.030 |
Why?
|
| Guanylate Kinases | 1 | 2015 | 12 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2016 | 71 | 0.030 |
Why?
|
| Anticipation, Psychological | 1 | 2015 | 10 | 0.030 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 1 | 2015 | 16 | 0.030 |
Why?
|
| Heterozygote | 1 | 2016 | 382 | 0.030 |
Why?
|
| Child | 2 | 2021 | 7355 | 0.030 |
Why?
|
| Cell Adhesion Molecules | 1 | 2015 | 174 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2018 | 811 | 0.030 |
Why?
|
| Data Collection | 1 | 2015 | 370 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2016 | 884 | 0.030 |
Why?
|
| Psychological Tests | 1 | 2014 | 88 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2020 | 9099 | 0.030 |
Why?
|
| Interpersonal Relations | 1 | 2015 | 177 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2021 | 1053 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2015 | 304 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2015 | 711 | 0.020 |
Why?
|
| Social Marketing | 1 | 2013 | 11 | 0.020 |
Why?
|
| Poison Control Centers | 1 | 2013 | 18 | 0.020 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2013 | 53 | 0.020 |
Why?
|
| Health Status Disparities | 1 | 2015 | 219 | 0.020 |
Why?
|
| Global Health | 1 | 2013 | 208 | 0.020 |
Why?
|
| Visual Perception | 1 | 2014 | 334 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2019 | 7061 | 0.020 |
Why?
|
| Sex Characteristics | 1 | 1990 | 333 | 0.020 |
Why?
|
| Child Rearing | 1 | 1987 | 4 | 0.020 |
Why?
|
| Father-Child Relations | 1 | 1987 | 3 | 0.020 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2007 | 224 | 0.020 |
Why?
|
| Gender Identity | 1 | 1987 | 58 | 0.020 |
Why?
|
| Psychotherapy | 1 | 1987 | 72 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2015 | 2465 | 0.010 |
Why?
|
| Data Interpretation, Statistical | 1 | 2007 | 306 | 0.010 |
Why?
|
| Life Style | 1 | 1987 | 183 | 0.010 |
Why?
|
| Social Support | 1 | 1987 | 233 | 0.010 |
Why?
|
| Aged | 1 | 2019 | 20434 | 0.010 |
Why?
|
| Child, Preschool | 1 | 1987 | 3829 | 0.010 |
Why?
|
| Animals | 1 | 1990 | 28155 | 0.010 |
Why?
|